Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Five-year OPTIC trial data confirm that starting ponatinib at 45 mg and stepping down to 15 mg once patients respond is the optimal strategy for resistant chronic myeloid leukemia (CML). Patients with BCR::ABL1 T315I mutations benefit most from the higher starting dose, while mutation testing at the point of treatment failure helps clinicians personalize therapy and manage cardiovascular risk.
Five-year follow-up data from the randomized phase 2 OPTIC trial have cemented a response-based dosing strategy for ponatinib (Iclusig) in patients with resistant chronic-phase CML. The trial enrolled 283 patients who had failed at least two prior TKIs or harbored a BCR::ABL1 T315I mutation, randomizing them to starting doses of 45 mg, 30 mg, or 15 mg daily — with the two higher-dose arms stepping down to 15 mg once BCR::ABL1 transcript levels hit ≤1% on the International Scale.
The 45 mg start-then-reduce approach emerged as the clear winner, particularly for patients with T315I mutations. Expert Jorge Cortes, MD, emphasizes confirming a sustained response before stepping down the dose to avoid losing hard-won disease control. He also highlights the growing role of mutation testing at the time of treatment failure, including next-generation sequencing (NGS) to uncover resistance mechanisms beyond BCR::ABL1 kinase domain mutations.
By the Numbers:
Why it matters: This strategy allows clinicians to maximize ponatinib's potency upfront — where it counts most — while reducing long-term cardiovascular exposure after response. It's now reflected in the drug's approved label, giving oncologists a data-backed roadmap for one of CML's toughest treatment scenarios.